About: The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database
Creator	Simmons, Heidi Robins, Harlan Svejnoha, Emily Baldo, Lance Dines, Jennifer Klinger, Mark Taniguchi, Ruth Manley, Thomas
source	MedRxiv
abstract	Background: Adaptive Biotechnologies has built an immune medicine platform based on the sequencing of immune receptors (immunoglobulins, B-cell receptors [BCRs] and T-cell receptors [TCRs]) with myriad applications in health and disease. This broad platform technology can be used to assess the diversity of the cellular adaptive immune system and track disease-associated TCRs and BCRs during the course of infection. The SARS-CoV-2 virus is spreading rapidly throughout the world, causing significant morbidity and mortality. Researchers, governments, and biotechnology companies are mobilizing to develop and distribute diagnostic and therapeutic alternatives to try to curb this global pandemic. Methods: In collaboration with our partners LabCorp/Covance, Adaptive Biotechnologies has opened the ImmuneRACE study to prospectively collect samples from individuals who have been infected with SARS-CoV-2, who have recovered from SARS-CoV-2 infection, or who have been exposed to someone infected with SARS-CoV-2. Discussion: We believe that the information contained within the genetics of the adaptive immune response to SARS-CoV-2 can improve our understanding of the immunobiology of this devasting virus and may inform efforts to improve current diagnostic and therapeutic approaches. To facilitate scientific and clinical advancement in the fight against COVID-19, the TCR sequence data resulting from the primary aims of this study will be made publicly available to scientists and researchers across the globe, an effort made possible through a collaboration with Microsoft. Trial registration: ImmunoRACE is registered with the US National Institutes of Health and can be accessed at ClinicalTrials.gov (NCT04494893).
has issue date	2020-08-21(xsd:dateTime)
bibo:doi	10.1101/2020.08.17.20175158
has license	medrxiv
sha1sum (hex)	c5c2090f010672adda7a0ba74b21afdb33ac1a26
schema:url	https://doi.org/10.1101/2020.08.17.20175158
resource representing a document's title	The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database
resource representing a document's body	covid:c5c2090f010672adda7a0ba74b21afdb33ac1a26#body_text
is schema:about of	named entity 'Immune' named entity 'COVID-19' named entity 'immune response' named entity 'blood samples' named entity 'medRxiv' named entity 'adaptive immune' named entity 'T-cell' named entity 'Covance' named entity 'medRxiv' named entity 'coronavirus disease' named entity 'coronaviruses' named entity 'gift card' named entity 'coronavirus disease' named entity 'T-cell' named entity 'preprint' named entity 'phlebotomist' named entity 'virus' named entity 'peer review' named entity 'sequence data' named entity 'WIRB' named entity 'HIPAA' named entity 'preprint' named entity 'infection' named entity 'antigen' named entity 'Seattle' named entity 'curate' named entity 'research staff' named entity 'preprint' named entity 'blood draw' named entity 'immunodominant' named entity 'ethnicity' named entity 'diagnostic procedures' named entity 'blood test' named entity 'lab tests' named entity 'fainting' named entity 'medRxiv' named entity 'gift card' named entity 'virus' named entity 'entire genome' named entity 'peer review' named entity 'immunodominant' named entity 'preprint' named entity 'coronavirus disease' named entity 'coronavirus disease' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'PBMCs' named entity 'tendon' named entity 'peptide' named entity 'BCR' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'public health' named entity 'ethnicity' named entity 'cellular immune response' named entity 'pregnant women' named entity 'TCRs' named entity 'immunodominant' named entity 'immune response' named entity 'Data analysis' named entity 'metadata' named entity 'human population' named entity 'coronavirus disease' named entity 'significant condition' named entity 'wards of the state' named entity 'diagnostic tests' named entity 'common cold' named entity 'asthma' named entity 'confidentiality' named entity 'antigen' named entity 'serum' named entity 'Clinical diagnosis' named entity 'Biological Substance' named entity 'memory T cells' named entity 'peer review' named entity 'immune response' named entity 'medRxiv' named entity 'clinical outcomes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software

About: The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database Goto Sponge NotDistinct Permalink

About: The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODEâ¢ Open Access Database Goto Sponge NotDistinct Permalink